sorbitol has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Guan, Y; Hitomi, H; Kobara, H; Masaki, T; Nakano, D; Nishiyama, A; Sugaya, T; Uemura, A; Zhang, Y | 1 |
1 review(s) available for sorbitol and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorbitol and su 11248
| Article | Year |
|---|---|
A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Animals; Blood Glucose; Capillaries; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrosis; Gene Knockdown Techniques; Glucose Transporter Type 2; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Receptors, Vascular Endothelial Growth Factor; Reperfusion Injury; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |